Abstract
One-hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette-Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs-Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients treated with C. parvum.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
BCG Vaccine / therapeutic use*
-
Bacterial Vaccines / therapeutic use*
-
Evaluation Studies as Topic
-
Female
-
Humans
-
Male
-
Melanoma / therapy*
-
Middle Aged
-
Neoplasm Staging
-
Propionibacterium / immunology*
-
Random Allocation
-
Recurrence
-
Skin Neoplasms / therapy*
-
Time Factors
Substances
-
BCG Vaccine
-
Bacterial Vaccines